Nasdaq IPOs

Decarbonization Plus Acquisition, the third blank check company formed by Riverstone targeting businesses advancing global decarbonization, raised $200 million by offering 20 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisa

Helix Acquisition, a blank check company formed by Cormorant Asset Management targeting healthcare, raised $100 million by offering 10 million shares at $10. Unlike an ordinary SPAC, the company did not offer warrants that would become exercisable following completion of the init

Cerberus Telecom Acquisition, a blank check company formed by Cerberus Capital Management targeting the ICT industry, lowered the proposed deal size for its upcoming IPO on Monday. The New York, NY-based company now plans to raise $300 million by offering 30 million units at a p

Compass Therapeutics, a Phase 1 immuno-oncology biotech developing novel protein and antibody therapies, filed on Monday with the SEC to raise up to $50 million in an initial public offering. The company previously filed in August 2020 for a $261 million secondary offering,

Foghorn Therapeutics, a preclinical biotech developing gene therapies for hematologic cancers and solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $120 million by offering 7.5 million shares at a price range of $15 to $17. At th

Abcam, which provides biological reagents and tools for research, drug discovery, and diagnostics, announced terms for its US IPO on Monday. The Cambridge, United Kingdom-based company plans to raise $148 million by offering 8.9 million ADSs at $16.52, the as-converted last clos

NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, announced terms for its IPO on Monday. The Stans, Switzerland-based company plans to raise $20 million by offering 3.6 million units at a price range of $5 to $6. Ea

Updated Monday, 10/19. Five IPOs and two SPACs are expected to raise $2.1 billion in the week ahead, led by leading cybersecurity brand McAfee (MCFE). Taken private by Intel in 2011, McAfee (MCFE) plans to raise $759 million at a $9.6 billion market cap in its return to the pub

Three IPOs and one SPAC are expected to raise $1.6 billion in the week ahead, led by leading cybersecurity brand McAfee (MCFE). Taken private by Intel in 2011, McAfee (MCFE) plans to raise $759 million at a $9.6 billion market cap in its return to the public market. McAfee provi

IPO activity has remained robust ahead of the U.S. presidential election as Nasdaq welcomed more than two dozen companies since the beginning of the month, including 14 this week. The momentum builds upon the red-hot IPO market in September, during which Nasdaq held 40 IPOs.

Nine IPOs and five SPACs went public this past week, and one IPO postponed. New filing activity continued to pump the breaks as we near the election, with just one new IPO filing. SPAC activity continued unabated however as nine submitted initial filings. The largest deal of th

IN8bio, a Phase 1 biotech developing allogeneic T cell therapies for cancer and solid tumors, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The company's pipeline contains lead candidates INB-200, which is currently in a Phase 1 trial for

dMY Technology Group III, the third blank check company formed by Niccolo de Masi and Harry You targeting an app business, filed on Friday with the SEC to raise up to $250 million in an initial public offering. The Las Vegas, NV-based company plans to raise $250 million by offer

Opthea, an Australian Phase 3 biotech developing VEGF inhibitors for wet AMD, raised $128 million by offering 9.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on the ASX (OPT). The ADS equivalents offered consisted of 8.6 million ADSs and pre

Gatos Silver, a US producer of silver and other precious metals, announced terms for its IPO on Friday. It plans to dual-list its shares on the NYSE and the Toronto Stock Exchange. The Greenwood Village, CO-based company plans to raise $150 million by offering 18.8 million

William Penn Bancorporation, a Pennsylvania -based bank with twelve full-service branches, filed to list on the Nasdaq in a subscription offering on Thursday.  Note: Renaissance Capital will not track William Penn Bancorporation's listing in our 2020 IPO stat

Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, raised $15 million by offering 1.3 million shares at $12, the low end of the range of $12 to $14. Kiromic BioPharma plans to list on the Nasdaq under the symbol KRBP. ThinkEqu

Bridgetown Holdings, a blank check company formed by Pacific Century and Thiel Capital targeting "new economy" sectors in Southeast Asia, raised $550 million by offering 55 million units at $10. The company originally planned to offer 50 million units before increasing the unit o

Aligos Therapeutics, a Phase 1 biotech developing oligonucleotide therapies for viral and liver diseases, raised $150 million by offering 10 million shares at $15, within the range of $14 to $16.  Aligos Therapeutics plans to list on the Nasdaq under the symbol ALGS. J.P. M

Tarsus Pharmaceuticals, a Phase 3 biotech developing therapies for ophthalmic conditions, raised $88 million by offering 5.5 million shares at $16, within the range of $15 to $17. The company offered 0.5 million more shares than anticipated. At pricing, the company raised 10% mor